Spots Global Cancer Trial Database for postmenopausal women
Every month we try and update this database with for postmenopausal women cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| Green Tea in Breast Cancer Patients | NCT00949923 | Incident Breast... | tea capsule | 18 Years - | University of Southern California | |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study | NCT00580788 | Osteoporosis Humoral Hyperca... Hyperparathyroi... | PTHrP (1-36) | 24 Years - 35 Years | University of Pittsburgh | |
| MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk | NCT01649661 | Cancer Free Wom... | questionnaire | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Vitamin D, Diet and Activity Study | NCT01240213 | Breast Cancer Obesity Hypovitaminosis... | Vitamin D Placebo | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | NCT00128843 | Breast Cancer | Exemestane Anastrozole | 18 Years - 90 Years | Spanish Breast Cancer Research Group | |
| Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) | NCT01129622 | Breast Cancer | letrozole | 40 Years - 80 Years | Mount Sinai Hospital, Canada | |
| Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study | NCT00359060 | Breast Cancer | Physical activi... | 50 Years - 69 Years | UMC Utrecht | |
| Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia | NCT05800197 | Breast Cancer Neoadjuvant End... | Tamoxifen 20mg Anastrozole 1mg Letrozole 2.5mg Goserelin Triptorelin | 18 Years - | Blokhin's Russian Cancer Research Center | |
| A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) | NCT01740427 | Breast Neoplasm... | PD-0332991 Letrozole Placebo Letrozole | 18 Years - | Pfizer | |
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | NCT00213980 | Breast Cancer | Zoledronate | 18 Years - | University of Wisconsin, Madison | |
| A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] | NCT02297438 | Breast Neoplasm... | Palbociclib Letrozole Placebo Letrozole | 18 Years - 70 Years | Pfizer | |
| One Week Comparison Study of PTH and PTHrP Infusions | NCT01333267 | Osteoporosis Hypercalcemia o... Hyperparathyroi... Bone Diseases, ... | Parathyroid Hor... parathyroid hor... PTH (1-34) and ... | 24 Years - 35 Years | University of Pittsburgh | |
| Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | NCT00128843 | Breast Cancer | Exemestane Anastrozole | 18 Years - 90 Years | Spanish Breast Cancer Research Group | |
| Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy | NCT00050011 | Breast Neoplasm... Osteoporosis | Zoledronic Acid Letrozole | 18 Years - 85 Years | Novartis | |
| A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] | NCT02297438 | Breast Neoplasm... | Palbociclib Letrozole Placebo Letrozole | 18 Years - 70 Years | Pfizer | |
| Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | NCT01004744 | Invasive Breast... | Anastrozole | 21 Years - | Columbia University | |
| Vitamin D, Diet and Activity Study | NCT01240213 | Breast Cancer Obesity Hypovitaminosis... | Vitamin D Placebo | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) | NCT01129622 | Breast Cancer | letrozole | 40 Years - 80 Years | Mount Sinai Hospital, Canada | |
| Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | NCT00213980 | Breast Cancer | Zoledronate | 18 Years - | University of Wisconsin, Madison | |
| Quality Of Life While Receiving Faslodex | NCT00643513 | Breast Cancer | 18 Years - | AstraZeneca | ||
| Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | NCT01004744 | Invasive Breast... | Anastrozole | 21 Years - | Columbia University | |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI) | NCT01129622 | Breast Cancer | letrozole | 40 Years - 80 Years | Mount Sinai Hospital, Canada | |
| An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women | NCT05038878 | Mild Autonomous... | Elagolix | - | Icahn School of Medicine at Mount Sinai | |
| Patient's Anastrozole Compliance to Therapy Programme | NCT00555867 | Breast Cancer | Anastrozole | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
